Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Exelixis Inc
(NQ:
EXEL
)
21.69
+0.91 (+4.38%)
Official Closing Price
Updated: 4:15 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis Inc
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
June 21, 2022
From
Exelixis, Inc.
Via
Business Wire
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
June 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Exelixis-BioInvent Establish Immuno-Oncology Pact
June 16, 2022
Via
Benzinga
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
June 16, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
May 31, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
May 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
May 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on
May 24, 2022
Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning!
Via
InvestorPlace
This Biotech Looks Good With Increased M&A activity
May 20, 2022
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for...
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
May 19, 2022
Via
Benzinga
Exelixis: Q1 Earnings Insights
May 10, 2022
Exelixis (NASDAQ:EXEL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by...
Via
Benzinga
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022
From
Exelixis, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
May 04, 2022
From
Exelixis, Inc.
Via
Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
May 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
May 03, 2022
Via
Benzinga
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
April 26, 2022
From
Exelixis, Inc.
Via
Business Wire
7 Top-Rated Biotech Stocks to Buy for Q2
April 21, 2022
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.
Via
InvestorPlace
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
April 14, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
April 13, 2022
From
Exelixis, Inc.
Via
Business Wire
Friday Markets News
March 25, 2022
Methane leaks in the Permian Basin are 6 times higher than estimates.
Via
Talk Markets
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
March 25, 2022
Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have
Via
Benzinga
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
March 25, 2022
From
Exelixis, Inc.
Via
Business Wire
Flood Helping Ukraine
March 24, 2022
Emerging markets are gaining as mature markets look risky.
Via
Talk Markets
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...
Via
Benzinga
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
March 14, 2022
From
Exelixis, Inc.
Via
Business Wire
Futures Flat As Traders Brace For Op-Ex Volatility, More Ukraine Headlines
February 18, 2022
In the latest geopolitical developments Russian Foreign Minister Sergei Lavrov agreed to meet US Secretary of State Antony Blinken for talks in Europe next week; German Chancellor Olaf Scholz will host...
Via
Talk Markets
Exelixis: Q4 Earnings Insights
February 17, 2022
Exelixis (NASDAQ:EXEL) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.